NEW YORK, May 7 - Lynx Therapeutics of Hayward, Calif., today announced that it has entered a service agreement with the National Institute on Aging of the NIH to study stem cell gene expression using its MPSS technology.
Â
Lynx will receive payments for the services it performs on samples provided by the NIA under this agreement. Further details were not provided.
Â
The company said that an analysis of human astrocyte precursor cells undertaken for Cue Therapeutics helped propel the NIA to initiate analysis of additional human stem cells using Lynx's massively parallel signature sequencing technology.